Search research articles
Contact Us
Filters
Showing results (141-150 of 156) with videos related to
Page
of 16
Sort By:
The Journal of Small Animal Practice
|
November 19, 2021
Prevalence, association with systemic inflammatory response syndrome and outcome of stress hyperglycaemia in sick cats
P S Frezoulis, I L Oikonomidis, M N Saridomichelakis, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|
March 28, 2012
UK emissions of the greenhouse gas nitrous oxide
U Skiba, S K Jones, U Dragosits, et al.
AIDS Research and Human Retroviruses
|
April 13, 2010
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
Lisa L Ross, Winkler G Weinberg, Edwin DeJesus, et al.
Nature Communications
|
November 10, 2016
Experimental verification of multipartite entanglement in quantum networks
W McCutcheon, A Pappa, B A Bell, et al.
AIDS Research and Human Retroviruses
|
March 27, 2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Charles B Hicks, Edwin DeJesus, Louis M Sloan, et al.
Scientific Reports
|
July 18, 2018
Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human malignant melanoma
T Mantso, S Vasileiadis, I Anestopoulos, et al.
HIV Medicine
|
January 20, 2006
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity
P N Kumar, A Rodriguez-French, M A Thompson, et al.
Journal of Clinical Pharmacology
|
June 1, 1990
Pharmacokinetics of oral and transdermal triprolidine
M V Miles, R Balasubramanian, A W Pittman, et al.
Pharmacology & Therapeutics
|
October 25, 2022
Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises
I Anestopoulos, S Kyriakou, V Tragkola, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 156) with videos related to
Sort By:
Page
of 16
The Journal of Small Animal Practice
|
November 19, 2021
Prevalence, association with systemic inflammatory response syndrome and outcome of stress hyperglycaemia in sick cats
P S Frezoulis, I L Oikonomidis, M N Saridomichelakis, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|
March 28, 2012
UK emissions of the greenhouse gas nitrous oxide
U Skiba, S K Jones, U Dragosits, et al.
AIDS Research and Human Retroviruses
|
April 13, 2010
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
Lisa L Ross, Winkler G Weinberg, Edwin DeJesus, et al.
Nature Communications
|
November 10, 2016
Experimental verification of multipartite entanglement in quantum networks
W McCutcheon, A Pappa, B A Bell, et al.
AIDS Research and Human Retroviruses
|
March 27, 2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Charles B Hicks, Edwin DeJesus, Louis M Sloan, et al.
Scientific Reports
|
July 18, 2018
Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human malignant melanoma
T Mantso, S Vasileiadis, I Anestopoulos, et al.
HIV Medicine
|
January 20, 2006
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity
P N Kumar, A Rodriguez-French, M A Thompson, et al.
Journal of Clinical Pharmacology
|
June 1, 1990
Pharmacokinetics of oral and transdermal triprolidine
M V Miles, R Balasubramanian, A W Pittman, et al.
Pharmacology & Therapeutics
|
October 25, 2022
Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises
I Anestopoulos, S Kyriakou, V Tragkola, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Page
of 16